



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.  
11068-014-999

APPLICATION NO  
10/612,604

APPLICANT  
Huang *et al.*

FILING DATE  
July 1, 2003

GROUP  
1648

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SBC	C01	5,631,128	5/97	Kozal <i>et al.</i>	—	—	
	C02	5,650,268	7/97	Kozal <i>et al.</i>	—	—	
	C03	5,917,033	6/99	Modak <i>et al.</i>	—	—	
	C04	6,124,327	9/00	Silverman	—	—	
	C05	6,653,081	11/03	Whitcomb	—	—	
	C06	20040067487	4/04	Whitcomb	—	—	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
SBC	C07	WO99/67427	6/99	PCT	—	—		
	C08	WO99/61658	12/99	PCT	—	—		
	C09	WO02/22781	9/01	PCT	—	—		
	C10	International Search Report of PCT/US99/14486	6/99	PCT	—	—		
	C11	International Search Report of PCT/US01/28736	5/02	PCT	—	—		
	C12	International Search Report of PCT/US99/11629	9/99	PCT	—	—		
	C13	International Search Report of PCT/US01/18882	10/01	PCT	—	—		
	C14	Copy of International Search Report PCT/US03/21024	5/04	PCT	—	—		

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

SBC	C15	Ahluwalia, G. S., <i>et al.</i> (1996) "2', 3'-Didehydro-3 <sup>1</sup> -deoxythymidine: Regulation of its Metabolic Activation by Modulators of Thymidine-5'-triphosphate Biosynthesis" <i>Mol. Pharm.</i> 50: 160-165
	C16	Appelt, <i>et al.</i> , 1991 "Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis," <i>J. Med. Chem.</i> 34: 1925-1934
	C17	Arnold E., <i>et al.</i> (1995) "Structures of DNA and RNA Polymerases and Their Interactions with Nucleic Acid Substrates", <i>Curr Opin Struct Biol</i> 5:27-38;
	C18	Back, KT, et al, (1996) "Reduce Replication of 3TC-Resistant HIV-1 Variants in Primary Cells Due to a Processivity Defect of the Reverse Transcriptase Enzyme", <i>EMBO</i> 15: 4040-4049
	C19	Balzarini J, (1998) "A Novel Mutation (F227L) Arises in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 on Dose-Escalating Treatment of HIV Type 1-Infected Cell Cultures With the Nonnucleoside Reverse Transcriptase Inhibitor Thiocarboxanilide UC-781" <i>AIDS Res. Human</i> , 14(3):255-260

See	C20	Balzarini J, <i>et al.</i> (1997) "Zidovudine-Resistant Human Presence Immunodeficiency Virus Type 1 Strains Subcultured in the of Both Lamivudine and Quinoxaline HBY 097 Retain Marked Sensitivity to HBY 097 but not to Lamivudine" <i>J of Infect Dis</i> , 176:1392-1397
	C21	Balzarini J., <i>et al.</i> , (1992) "HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity Against HIV1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase", <i>Virology</i> 192:246-253
	C22	Barnes WM, (1994) "PCRAmplication of up to 35-kb DNA with High Fidelity and High Yeild from I. Bacteriophage Templates" <i>PNAS</i> 91:2216-2220
	C23	Bartenschlager R, <i>et al.</i> (1994) "Kinetic and Structural Analyses of Hepatitis C Virus Polyprotein Processing", <i>J. Virol.</i> 68:5045-5055
	C24	Boucher CAB, <i>et al.</i> (1993) "High-Level Resistance to (-) Enantiomeric 2'-Deoxy-3'-Thiacytidine In Vitro is Due to One Amino Acid Substitution in the Catalytic Site of Human Immunodeficiency Virus Type 1 Reverse Transcriptase", <i>Antimicrob Agents Chemother</i> , 37:2231-2234
	C25	Boucher CAB, <i>et al.</i> (1990) "Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy", <i>Lancet</i> 336:585-590
	C26	Boyer, <i>et al.</i> , "Analysis of Nonnucleoside Drug-Resistant Variants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <i>J. Virol.</i> , 67(4):2412-2420 (1993).
	C27	Cheeseman S.H., <i>et al.</i> (1995) "Phase I/II Evaluation of Defic Nevirapine Alone and in Combination with Zidvudine for Infection with Human Immunodeficiency Virus", <i>J Acquir Immune Syndr</i> 8:141-151
	C28	Coffin JM, (1995) "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy", <i>Science</i> 267:483-489
	C29	Craig C and Moyle G, (1997) "The development of resistance of HIV-1 to zalcitabine", <i>AIDS</i> 11:271-279.
	C30	Croteau G. <i>et al</i> (1997) "Impaired Fitness of Human Immunodeficiency Virus Type 1 Variants with High-Level Resistance to Protease Inhibitors" <i>J Virol</i> 71:1089-1096
	C31	D'Aquila R.T. (1994) "Molecular Pathogenesis and Laboratory Monitoring", <i>Clin Lab Med</i> 14:393-423
	C32	De Clercq E, (1997) "Development of Resistance of Human the 4); Immunodeficiency Virus (HIV) to Anti-HIV Agents: How to Prevent Problem" <i>Intl of Antimicro Agnts</i> , 9:21-36
	C33	De Clercq E, (1992) "HIV Inhibitors Targeted at the Revest Transcriptase", <i>AIDS Res. Hum Retrovin</i> 8:119-134
	C34	DeJong, M.D., <i>et al.</i> (1994) "Alternating Nevirapine and Infected Zidovudine Treatment of Human Immunodeficiency Virus Type 1Persons Does Not Prolong Nevirapine Activity", <i>J Infect Dis</i> 169:1346-1350
	C35	DeJong MD, <i>et al.</i> (1996) "Host-parasite Dynamics and Outgrowth of Virus Containing a Single K7OR Amino Acid Change in Reverse Transcriptase are Responsible for the Loss of Human Immunodeficiency Virus Type 1 RNA Load Suppression by Zidovudine", <i>PNAS</i> 93:5501-5506
	C36	Descamps <i>et al.</i> , 1997 "Susceptibility of Human Immunodeficiency Virus Type 1 Group 0 Isolates to Antiretroviral Agents: In Vitro Phenotypic and Genotypic Analyses," <i>Journal of Virology</i> 71(11): 8893-8898.
	C37	De Antoni A., <i>et al.</i> Mutations in a pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. <i>J. Infect Dis.</i> (1997) OCT.; 176(4): 899-903
	C38	Doyon L, <i>et al.</i> (1996) "Second Locus Involved in Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors", <i>J Virol</i> 70:3763-3769
	C39	Dueweke, T.J., <i>et al.</i> (1993) "A Mutation in Reverse to Other Transcriptase of Bis (Heteroaryl) Piperazine Resistant Human Immunodeficiency Virus Type 1. That Confers Increased Sensitivity; Nonnucleoside Inhibitors", <i>PNAS</i> 90:4713-4717
	C40	Eastman, P. Scott, <i>et al.</i> (1995) Monisotopic Hybridization Assay for Determination of Relative Amounts of Genotypic Human Micro, Immunodeficiency Virus Type 1 Zidovudine Resistance", <i>J Clin</i> 2777-2780
	C41	Fitzgibbon <i>et al.</i> Human Immunodeficiency virus type 1 pol gene mutations in an AIDS pateint treated with multiple antiretroviral drugs. <i>Journal of Virology</i> , vol. 67, No. 12 (1993) pp. 7271-7275.
	C42	Frenkel <i>et al.</i> Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. <i>Journal of Clinical Immunology</i> . vol. 33, No. 2 (1995) pp. 342-347.
	C43	Frost, S.D.W., and McLean, A.R. (1994) "Quasispecies Dynamics and the Emergence of Drug Resistance During Zidovudine Therapy of Hiv Infection", <i>AIDS</i> 8:323-332.
	C44	Gerondelis P, <i>et al.</i> (1999) "The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant is Replication Defective and Demonstrates Alternations in both RNA 5'-End-and DNA 3',-End-Directed RNase H Activities", <i>J Virol</i> 73: 5803-5813
	C45	Goulden MG, <i>et al.</i> (1996) "Selection In Vitro of an HIV-1 Variant Resistant to Both Lamivudine (3TC) and Zidvudine", <i>AIDS</i> 10:101-102.
✓	C46	Gu Z, <i>et al.</i> (1994) "Identification of Novel Mutations that Confer Drug Resistance In the Human Immunodeficiency Virus Polymerase Gene", <i>Leukemia</i> 8(1):166-169.

SBC	C47	Hammond, <i>et al.</i> , 1998 "Mutations in Retroviral Genes Associated with Drug Resistance," 36-79.
	C48	Harrigan PR, et al, (1998) "Relative Replication Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro", <i>J Virol</i> . 72:3773-3778
	C49	Ho DD, et al, (1994) "Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to a C2-Symmetric Protease Inhibitor", <i>J Virol</i> 68:2016-2020
	C50	Holodniy, Mark, <i>et al.</i> (1995) "Determination of Human Immunodeficiency Virus RNA In Plasma and Cellular Viral DNA Genotypic Zidovudine Resistance Combination Therapy", <i>J Virol</i> , 3510-3516
	C51	Hazuda, <i>et al.</i> , 2000 "Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells," <i>Science</i> 287: 646-650.
	C52	Iversen <i>et al.</i> "Multidrug-resistant immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy," <i>Journal of Virology</i> . vol. 70, No. 2 (1996) pp. 1086-1090.
	C53	Kellam, P., <i>et al.</i> (1994) "Zidovudine Treatment Results in the Selection of Human Immunodeficiency Virus Type 1 Variants Whose Genotypes Confer Increasing Levels of Drug Resistance", <i>J Gen Virol</i> 75:341-351.
	C54	Kim EE, et al, (1995) "Crystal Structure of HIV-1 Protease in Complex with VX-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme", <i>J Am Chem Soc.</i> 117: 1181-1182
	C55	Kleim, J., <i>et al.</i> (1997) "In vitro Selection for Different Mutational Patterns in the HIV-1 Reverse Transcriptase Using High and Low Selective Pressure of the Nucleoside Reverse Transcriptase inhibitor HBY 097" <i>Virology</i> . 231: 112-118
	C56	Kosalaraksa P, et al, (1999) "Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay", <i>J Virol</i> 73:5356-5363.
	C57	Krebs, R., <i>et al.</i> 1997 "Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC" <i>Biochemistry</i> 36: 10292-10300
	C58	Kuritzkes D.R. Clinical significance of drug resistance in HIV-1 infection. <i>AIDS</i> (1996) vol. 10, S27-S31.
	C59	Larder BA, (1992) "3'-Azido-3'-Deoxythymidine Resistance Suppressed by a Mutation Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Reverse Transcriptase Inhibitors", <i>Antimicrob Agents Chemother</i> 36: 2664-2669.
	C60	Larder BA, et al, (1991) "Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes", <i>AIDS</i> 5:137-144.
	C61	Larder BA, et al, (1995) "Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy", <i>Science</i> 269:696-699.
	C62	Lieven Stuyver, <i>et al.</i> (1997) "Line Probe Assay For Rapid Detection Of Drug Selected Mutations In The Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene", <i>Antimicrob Agents Chemother</i> , 284-291
	C63	Lin PF, et al, (1994) "Genotypic and Phenotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from Patients on Prolonged Stavudine Therapy", <i>J Infect Disease</i> 170:1157-1164.
	C64	Lopez-Galindez C, et al, (1991) "Characterization of genetic variation and 3'-azido-3'-deoxythymidine-resistance mutations of human immunodeficiency virus by the Rnase A mismatch cleavage method", <i>PNAS</i> 88:4280-4284 (Exhibit 36).
	C65	Mammamo F, et al, (1998) "Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease and gag Coevolution in Protease Inhibitor-Treated Patients", <i>J Virol</i> 72:7632-7637
	C66	Maschera B, et al, (1996) "Mutations in the Viral Protease that Confer Resistance to Saquinavir Increase the Dissociation Rate Constant of the Protease-Saquinavir Complex", <i>Bio Chem</i> 271:33231-33235.
	C67	Mayers DL, et al, (1992) "Characterization of HIV Isolates Arising After Prolonged Zidovudine Therapy", <i>J Acq Imm Def Synd</i> 5:749-759
	C68	Moyle GJ (1996) "Use of Viral Resistance Patterns to Antiretroviral Drugs in Optimising Selection of Drug Combinations and Sequences", <i>Drugs</i> 52:168-185
	C69	Mohri, H., <i>et al.</i> (1993) "Quantitation of Zidovudine Resistant Human Immunodeficiency Virus Type 1 in the Blood of Treated and Untreated Patients", <i>PNAS</i> 90:25-29
	C70	Mulligan RC and Berg P, (1980) "Expression of a Bacterial Gene in Mammalian Cells", <i>Science</i> 209:1422-1427
	C71	Nájera, I., <i>et al.</i> (1994) "Natural Occurrence of Drug Resistance Mutations in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Isolates", <i>Aids Res Hum Retroviruses</i> 10:1479-1488
	C72	Nájera, I., <i>et al.</i> (1995) "pol Gene Quasispecies of Human Immunodeficiency Virus: Mutations Associated with Drug Resistance in virus from Patients Undergoing No Drug Therapy", <i>J Virol</i> 69:23-31
V	C73	Nunberg, J.H., <i>et al.</i> (1990) "Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors", <i>J Virol</i> 65:4887-4892

sbe	C74	Pelemans H, <i>et al.</i> (1997) "Characteristics of the Pro225His Mutation in Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase That Appears Under Selective Pressure of Dose Escalating Quinoxaline Treatment of HIV-1" <i>J. Virol.</i> 71(11) :8195-8203
	C75	Richman, D.D. <i>et al.</i> (1994) "Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy", <i>J Virol</i> 68:1660-1666
	C76	Richman, D.D. <i>et al.</i> (1991) "Human Immunodeficiency Virus Type 1 Mutants Resistant to Nonnucleoside Inhibitors of Reverse Transcriptase Arise in Tissue Culture", <i>PNAS</i> 88:11241-11245
	C77	Sanger, <i>et al.</i> (1977) "DNA Sequencing with Chain-terminating Inhibitors", <i>PNAS</i> 88: 11241-245.
	C78	Sakar, G. and Sommer, S.S. (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis" <i>Biotech.</i> 8(4):404-407
	C79	Shafer RW, <i>et al.</i> (1994) "Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of pol Gene Mutations", <i>J Infect Disease</i> 169:722-729
	C80	Shirasaka T, <i>et al.</i> (1995) "Emergence of Human Immunodeficiency Virus Type 1 Variants with Resistance to Multiple Deoxynucleosides in Patients Receiving Therapy with Dideoxynucleosides", <i>PNAS</i> 92:2398-2402
	C81	Southern, <i>et al.</i> (1982) "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", <i>Appl. Genet</i> 1:327-341
	C82	Strair RK, <i>et al.</i> (1993) "Recombinant Retroviral Systems For the Analysis of Drug Resistant HIV" <i>Nucl Acids Res.</i> 21(20): 4836-4842
	C83	Sugden B, <i>et al.</i> (1985) "A Vector that Replicates as a Plasmid and can be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus", <i>Mol Cell Bio</i> 5:410-413.
	C84	Tisdale M, <i>et al.</i> (1993) "Rapid In Vitro Selection of Human Immunodeficiency Virus Type 1 Resistant to 3'-Thiacytidine Inhibitors due to a Mutation in the YMDD Region of Reverse Transcriptase", <i>PNAS</i> 90:5653-5656.
	C85	Vacca JP, <i>et al.</i> (1994) "L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor", <i>PNAS</i> 91:4096-4100.
	C86	Villahermosa, ML, <i>et al.</i> "Evaluations of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors" <i>Antiviral Ther.</i> (1998); 3(4):221-227
	C87	Zennou V, (1998) "Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo", <i>J. Virol.</i> , 72:3300-3306.
	C88	Zhang Y, <i>et al.</i> (1997) "Drug Resistance During Indinavir Therapy is Caused by Mutations in the Protease Gene and in its Gag Substrate Cleavage Sites", <i>J Virol</i> 71:6662-6670.
↓	C89	Zhang D, <i>et al.</i> (1994) "Resistance to 2',3'-Dideoxycytidine Conferred by a Mutation in Codon 65 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase", <i>Antimicrob Agents Chemother</i> 38:282-287

EXAMINER <i>Haey B. Chen</i>	DATE CONSIDERED <i>September 14, 2004</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

11068-014-999

APPLICATION NO

10/612,604

APPLICANT

Huang et al.

FILING DATE

July 1, 2003

GROUP

1645 1648

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SDe	A01	5,436,131	7/25/95	Condra et al.	—	—	
	A02	5,837,464	11/17/98	Capon et al.	—	—	
	A03	6,103,462	8/15/00	Paulous et al.	—	—	
✓	A04	6,242,187	6/5/01	Capon et al.	—	—	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
SDe	A05	WO99/67427	6/99	PCT	—	—	

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

SDe	A06	Gervais, <i>et al.</i> , "A New Reporter Cell Line to Monitor HIV Infection and Drug Susceptibility <i>in Vitro</i> ", Proc. Natl. Acad. Sci. USA (1997), Vol. 94 pgs 4653-4658.
	A07	Herrmann, <i>et al.</i> , "A Working Hypotheses-Virus Resistance Development As An Indicator of Specific Antiviral Activity", Ann. NY Acad Sciences (1997), 284: 632-637.
	A08	Hertogs, <i>et al.</i> , "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates From Patients Treated with Antiretroviral Drugs", Antimicrobial Agents and Chemotherapy (1998) 42(2): 269-276.
	A09	Lie, <i>et al.</i> , "Advances In Quantitative PCR Technology: 5' Nuclease Assays", Curr Opinion Biotech (1998), 9(1): 43-48.
	A10	Nijhuis, <i>et al.</i> , "Implications of Antiretroviral Resistance on Viral Fitness", Curr. Opin. Infect Diseases (2001), 14: 23-28.
	A11	Petropoulos, <i>et al.</i> , "A Novel Phenotypic Drug Susceptibility Assay For Human Immunodeficiency Virus Type 1", Antimicrobial Agents and Chemotherapy (2000), 44(4): 920-928.
	A12	Race, <i>et al.</i> , "Analysis of HIV Cross-Resistance to Protease Inhibitors Using A Rapid Single-Cycle Recombinant Virus Assay For Patients Failing On Combination Therapies", AIDS (1999), 13(15): 2061-2068.
✓	A13	Shi, <i>et al.</i> , "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to reverse Transcriptase Inhibitors", Antimicrobial Agents and Chemotherapy (1997) 41(12): 2781-85.

EXAMINER

Haley B. Chen

DATE CONSIDERED

September 14, 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO.

11068-014-999

APPLICATION NO

10/612,604

APPLICANT

Huang et al.

FILING DATE

July 1, 2003

GROUP

1645 1648

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SBe	B01	6,033,902	3/7/00	Haseltine et al.	-	-	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

Stacy B. Chen

DATE CONSIDERED

September 14, 2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.